YU1299A - 1,4-disupstituisani derivati piperidina koji sadrže fluor - Google Patents

1,4-disupstituisani derivati piperidina koji sadrže fluor

Info

Publication number
YU1299A
YU1299A YU1299A YU1299A YU1299A YU 1299 A YU1299 A YU 1299A YU 1299 A YU1299 A YU 1299A YU 1299 A YU1299 A YU 1299A YU 1299 A YU1299 A YU 1299A
Authority
YU
Yugoslavia
Prior art keywords
substituted
fluorine
hydrogen atoms
heteroarylalkenyl
arylalkenyl
Prior art date
Application number
YU1299A
Other languages
English (en)
Inventor
Yoshimi Tsuchiya
Takashi Nomoto
Hirokazu Ohsawa
Kumiko Kawakami
Kenji Ohwaki
Masaru Nishikibe
Original Assignee
Banyu Pharmaceutical Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharmaceutical Co.Ltd. filed Critical Banyu Pharmaceutical Co.Ltd.
Publication of YU1299A publication Critical patent/YU1299A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na nove 1,4-disupstituisane derivate piperidina koji sadrze fluor, opisane opstom formulom (I) i na njihove farmaceutski prihvatljive soli, pri cemu: Ar predstavlja aril- ili heteroaril-grupu sa 1 do 2 hetero-atoma odabrana iz grupe koja se sastoji od azota, kiseonika i sumpora (od 1 do 3 atoma vodonika u prstenu navedene aril- ili heteroaril-grupe mogu da budu supstituisani nizom alkil-grupom, itd.); R1 predstavlja cikloalkil-grupu sa 3 do 6 atoma ugljenika, cijih od 1 do 4 atoma vodonika mogu da budu supstituisani fluorom; R2 predstavlja zasicenu ili nezasicenu alifaticnu ugljovodonicnu grupu sa 5 do 15 ugljenikovih atoma, cijih od 1 do 6 atoma vodonika mogu da budu supstituisani fluorom, aralkil-, arilalkenil-, heteroarilalkil- ili heteroarilalkenil-grupu sa 1 do 2 hetero-atoma odabrana iz grupe koja se sastoji od azota, kiseonika i sumpora (opciono, od 1 do 3 atoma vodonika u prstenu navedene aralkil-, arilalkenil-, heteroarilalkil- ili heteroarilalkenil-grupe mogu da budu supstituisani nizom alkil-, trifluormetil-, cijano-, hidroksi-, nitro-, nizom alkoksikarbonil-, halo-, nizom alkoksi- ili amino-grupom itd.; a X predstavlja O ili NH, pod uslovom da barem jedna od grupa R1, odnosno R2 sadrzi jedan ili vise atoma fluora. Jedinjenja iz ovog pronalaska pokazuju selektivno antagonisticko dejstvo prema muskarinskim M3 receptorima, kao i i odlicnu oralnu aktivnost, trajanje dejstva i farmakokinetiku, imaju malo sporednih efekata, bezbedna su i efikasna. Zbog toga su korisna pri lecenju ili profilaksi respiratornih, digestivnih i urinarnih oboljenja.
YU1299A 1996-08-01 1997-07-28 1,4-disupstituisani derivati piperidina koji sadrže fluor YU1299A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21943696 1996-08-01
JP5397997 1997-02-21

Publications (1)

Publication Number Publication Date
YU1299A true YU1299A (sh) 2002-03-18

Family

ID=26394715

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1299A YU1299A (sh) 1996-08-01 1997-07-28 1,4-disupstituisani derivati piperidina koji sadrže fluor

Country Status (29)

Country Link
US (2) US5948792A (sh)
EP (1) EP0930298B1 (sh)
JP (1) JP3063164B2 (sh)
KR (1) KR20000022214A (sh)
CN (1) CN1226888A (sh)
AR (3) AR008272A1 (sh)
AT (1) ATE229941T1 (sh)
AU (1) AU716050B2 (sh)
BG (1) BG103114A (sh)
BR (1) BR9711108A (sh)
CA (1) CA2261680C (sh)
CO (1) CO4960641A1 (sh)
CZ (1) CZ33199A3 (sh)
DE (1) DE69718026T2 (sh)
EE (1) EE9900038A (sh)
ES (1) ES2188961T3 (sh)
HR (1) HRP970426A2 (sh)
HU (1) HUP9902381A3 (sh)
ID (1) ID17259A (sh)
IL (1) IL127685A0 (sh)
IS (1) IS4960A (sh)
NO (1) NO990472L (sh)
NZ (1) NZ333842A (sh)
PE (1) PE92198A1 (sh)
PL (1) PL331431A1 (sh)
SK (1) SK12299A3 (sh)
TR (2) TR200001482T2 (sh)
WO (1) WO1998005641A1 (sh)
YU (1) YU1299A (sh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180823B1 (en) 1998-11-06 2001-01-30 Sepracor Inc. Stereoselective process for alkyl phenylglycolic acids
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
WO2000061572A1 (en) * 1999-04-08 2000-10-19 Merck & Co., Inc. Diastereoselective preparation of michael adducts
WO2000066579A1 (fr) * 1999-04-28 2000-11-09 Banyu Pharmaceutical Co., Ltd. Methodes de preparation de derives de piperidylmethylpyridine
AU6686700A (en) * 1999-08-23 2001-03-19 H. Lundbeck A/S Treatment of urinary incontinence
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
JP4782342B2 (ja) * 1999-12-17 2011-09-28 サノフィ−アベンティス フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6469172B2 (en) 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
WO2002004402A1 (fr) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Derives d'ester
CA2441896A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
CN1250545C (zh) 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
KR20040039436A (ko) * 2001-09-27 2004-05-10 파마시아 에이비 약학 조성물
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en) 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US6583103B1 (en) 2002-08-09 2003-06-24 S.C. Johnson & Son, Inc. Two part cleaning formula resulting in an effervescent liquid
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
JP2006506392A (ja) * 2002-10-29 2006-02-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP2177511A2 (en) 2002-12-10 2010-04-21 Ranbaxy Laboratories Limited Process for preparing 3,6-disubstituted azabicyclo derivatives
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
DE60225195T2 (de) 2002-12-23 2009-02-26 Ranbaxy Laboratories, Ltd. Flavaxat-derivate als muscarin-rezeptor antagonisten
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) * 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7592359B2 (en) 2003-04-10 2009-09-22 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
JP2007524641A (ja) 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
KR20060105872A (ko) * 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
WO2006005980A1 (en) * 2004-06-16 2006-01-19 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
WO2006018708A2 (en) * 2004-08-19 2006-02-23 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
US20080280883A1 (en) * 2004-09-24 2008-11-13 Mohammad Salman Muscarinic Receptor Antagonists
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
KR20070083939A (ko) 2004-11-02 2007-08-24 반유 세이야꾸 가부시끼가이샤 아릴옥시 치환된 벤즈이미다졸 유도체
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
US7799820B2 (en) * 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
EP1934184A1 (en) * 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. 3 -azabicyclooctane derivatives as muscarinic receptor antagonists
RU2008119323A (ru) 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Фармацевтические композиции мускаринового рецептора
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
PL2197841T3 (pl) 2007-09-07 2012-04-30 Theravance Inc Związki zawierające guanidynę przydatne jako antagoniści receptorów
MX2010006395A (es) * 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018661B2 (ja) * 1976-01-01 1985-05-11 太田製薬株式会社 １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
WO1996033973A1 (fr) * 1995-04-28 1996-10-31 Banyu Pharmaceutical Co., Ltd. Derives disubstitues en position 1,4 de piperidine
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
WO1997013766A1 (fr) * 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Derives heteroaromatiques substitues

Also Published As

Publication number Publication date
DE69718026T2 (de) 2003-07-10
BR9711108A (pt) 1999-08-17
PL331431A1 (en) 1999-07-19
JP3063164B2 (ja) 2000-07-12
EP0930298B1 (en) 2002-12-18
TR200001482T2 (tr) 2000-11-21
ID17259A (id) 1997-12-11
DE69718026D1 (de) 2003-01-30
CA2261680C (en) 2005-03-08
EE9900038A (et) 1999-08-16
US6040449A (en) 2000-03-21
CN1226888A (zh) 1999-08-25
CO4960641A1 (es) 2000-09-25
IL127685A0 (en) 1999-10-28
NO990472D0 (no) 1999-02-01
AU716050B2 (en) 2000-02-17
AR016877A2 (es) 2001-08-01
NO990472L (no) 1999-02-01
US5948792A (en) 1999-09-07
SK12299A3 (en) 2000-05-16
AR008272A1 (es) 1999-12-29
HUP9902381A3 (en) 2000-06-28
AU3635197A (en) 1998-02-25
AR017021A1 (es) 2001-08-22
TR199900204T2 (xx) 2000-01-21
PE92198A1 (es) 1999-01-09
EP0930298A1 (en) 1999-07-21
EP0930298A4 (en) 2000-06-07
CA2261680A1 (en) 1998-02-12
HRP970426A2 (en) 1998-08-31
KR20000022214A (ko) 2000-04-25
IS4960A (is) 1999-01-29
ES2188961T3 (es) 2003-07-01
HUP9902381A2 (hu) 1999-11-29
CZ33199A3 (cs) 1999-07-14
NZ333842A (en) 2001-05-25
ATE229941T1 (de) 2003-01-15
WO1998005641A1 (fr) 1998-02-12
BG103114A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
YU1299A (sh) 1,4-disupstituisani derivati piperidina koji sadrže fluor
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
EP1061076A4 (en) CYCLIC N-ACYLAMINE DERIVATIVES
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
HK1026700A1 (en) 1,4-Substituted cyclic amine derivatives or dihydroindole derivatives and medicament thereof.
KR960003604B1 (en) Benzimidazoline-2-oxo-1-carboxylic acid derivatives
MX19368A (es) Procedimiento para la preparacion de derivados heterociclicos que contienen nitrogeno benzofusionado y compuesto obtenido.
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
HUT62264A (en) Process for producing amidino compounds and pharmaceutical compositions comprising same as active ingredient
WO1996005166A1 (fr) Derive d'amine substitue et composition medicamenteuse le contenant
FI941863A (fi) Oksatsolidonijohdannainen
DE68925173D1 (de) 4-Methyl und 4-Ethyl substituierte Pyrrolidin-2-one
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
DE69428206D1 (de) Chinolincarbonsäurederivate und ihre salze
DE69407042D1 (de) Psoralen-derivate, deren herstellung und verwendung als arzneimittel
EP0794185A4 (en) BICYCLIC THIAZOLE COMPOUND